Xenon Pharmaceuticals joins Russell 3000, Russell 2000 Indexes
Xenon Pharmaceuticals (XENE) announced that the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025. The Russell 3000 Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000 Index measures the performance of the 2,000 smallest companies within the Russell 3000 Index. Inclusion in the Russell 2000 results in automatic inclusion in the appropriate growth and value style indexes. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately $10.6T in assets are benchmarked against Russell U.S. indexes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
6 hours ago
- Business Insider
RKLB, IONQ: 2 Soaring Russell 2000 Stocks Still Rated as Strong Buys
Small-cap stocks Rocket Lab (RKLB) and IonQ (IONQ) have both posted explosive gains over the last 12 months, catching the attention of growth-focused investors. Yet despite their big rallies, Wall Street analysts remain bullish, maintaining strong buy ratings on these Russell 2000 stocks. Confident Investing Starts Here: Nonetheless, RKLB and IONQ represent classic high-risk, high-reward opportunities, appealing to investors with a strong appetite for volatility and long-term disruption. While their sharp rallies reflect massive growth potential, both companies operate in emerging, capital-intensive sectors where success is not guaranteed. Let's dive into the details. Is RKLB a Good Stock to Buy? Rocket Lab builds and launches small satellite rockets, including its flagship Electron and upcoming reusable Neutron rocket. Over the last 12 months, RKLB stock soared more than 640%. Most recently, RKLB shares gained almost 12% on Thursday after securing a deal with the European Space Agency to launch two satellites for its LEO-PNT test constellation. Looking ahead, rising global tensions continue to fuel demand for Rocket Lab's defense and surveillance satellite launches, reinforcing the company's long-term potential. Its Electron rocket caters to the growing market for small satellite deployments, while the upcoming Neutron rocket, designed for medium-lift missions, positions Rocket Lab to meet the increasing demand for affordable and dependable space access. Furthermore, analysts remain optimistic. Top-rated analysts at firms like Cantor Fitzgerald and Stifel Nicolaus are bullish on the Neutron rocket, calling its planned launch in the second half of 2025 a critical milestone. They view it as a major step toward Rocket Lab's broader ambition of becoming a fully integrated space company. What Is the Target Price for RKLB? According to TipRanks, RKLB stock has received a Strong Buy consensus rating, with nine Buys and three Holds assigned in the last three months. The average Rocket Lab stock price target is $30.20, suggesting a potential downside of 16.4% from the current level. It's worth noting that despite analysts' bullish ratings, the recent surge in share price has pushed RKLB stock above its average price target, implying a potential downside in the near term. Is IonQ a Good Stock Buy? IonQ is a leading quantum computing company focused on trapped-ion technology, delivering its systems through major cloud platforms. Its stock has surged over 470% in the past year, reflecting its standout position in the space. IonQ is ahead of the curve, having already sold quantum hardware to cloud giants like Amazon's (AMZN) AWS and Alphabet's (GOOGL) Google Cloud. The company's systems offer full qubit connectivity and an industry-best 99.9% two-qubit gate fidelity, which is an essential metric indicating the system's ability to perform calculations with minimal error. With increasing demand and additional system deployments on the horizon, IonQ is well-positioned for further growth. Turning to Wall Street, five-star-rated analyst David Williams of Benchmark Co. recently reiterated his Buy rating on IonQ and earlier this month raised his price target to $50. His bullish stance follows IonQ's announcement to acquire UK-based Oxford Ionics in a $1.075 billion deal. Benchmark analysts believe the acquisition will significantly enhance IonQ's leadership in trapped-ion quantum computing by integrating Oxford's advanced technology, expanding its technical edge and global market reach. What Is IonQ Forecast for 2025? According to TipRanks, four out of five analysts currently covering IONQ stock have issued Buy recommendations. Meanwhile, the average IonQ share price target of $43 suggests a 4.6% upside from current levels.
Business Insider
9 hours ago
- Business Insider
Xenon Pharmaceuticals joins Russell 3000, Russell 2000 Indexes
Xenon Pharmaceuticals (XENE) announced that the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025. The Russell 3000 Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000 Index measures the performance of the 2,000 smallest companies within the Russell 3000 Index. Inclusion in the Russell 2000 results in automatic inclusion in the appropriate growth and value style indexes. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately $10.6T in assets are benchmarked against Russell U.S. indexes.
Associated Press
11 hours ago
- Associated Press
SBC Medical added to membership of Russell 3000® Index
IRVINE, Calif.--(BUSINESS WIRE)--Jun 27, 2025-- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical'), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000 ® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000 ® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 3000 ® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' 'targets' or 'hopes' or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are accessible on the SEC's website at View source version on CONTACT: SBC Medical Group Holdings Incorporated (Asia) Hikaru Fukui / Head of Investor Relations E-mail:[email protected] LLC (In the US) Bill Zima / Managing Partner Email:[email protected] KEYWORD: SOUTHEAST ASIA SINGAPORE NORTH AMERICA ASIA PACIFIC JAPAN EUROPE UNITED STATES UNITED KINGDOM CALIFORNIA INDUSTRY KEYWORD: MEDICAL SUPPLIES TECHNOLOGY PROFESSIONAL SERVICES OTHER HEALTH HEALTH HEALTH TECHNOLOGY MEDICAL DEVICES COSMETICS RETAIL DATA ANALYTICS SOFTWARE SOURCE: SBC Medical Group Holdings Incorporated Copyright Business Wire 2025. PUB: 06/27/2025 07:30 PM/DISC: 06/27/2025 07:31 PM
